/
NBRVF
$0.00+$0.00 (+0.00%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
50% from low
Exchange
OTC Link
OS
Borrow rate
43.89%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-0.95
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6.5M | $7.7M | $5.0M | $27.2M | $35.7M |
| Cost of revenue | $0 | $0 | $0 | $0 | $70.0K | $1.6M | $13.1M | $28.6M |
| Gross profit | $0 | $0 | $0 | $6.5M | $7.7M | $3.4M | $14.1M | $7.1M |
| Gross margin | — | — | — | 100.0% | 99.1% | 68.5% | 51.7% | 19.9% |
| R&D | $22.7M | $48.0M | $49.6M | $82.3M | $26.4M | $15.1M | $12.6M | $14.3M |
| Operating income | −$24.0M | −$55.0M | −$73.8M | −$114.4M | −$79.5M | −$66.1M | −$48.5M | −$55.5M |
| EBITDA | −$17.2M | −$54.4M | −$72.5M | −$114.1M | −$78.7M | −$66.9M | −$47.4M | −$54.7M |
| Net income | −$31.4M | −$54.9M | −$74.4M | −$114.8M | −$82.8M | −$69.5M | −$49.5M | −$57.2M |
| Net margin | — | — | — | -1765.8% | -1068.2% | -1382.2% | -181.7% | -160.3% |
| EPS (diluted) | -324.36 | -638.90 | -623.15 | -564.91 | -278.75 | -135.23 | -28.52 | -21.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $164M | $8.91 | $8.91–$8.91 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
NABRIVA THERAPEUTICS NEW
NABRIVA THERAPEUTICS NEW
Held by traders on TradeandTell
No one on the platform currently holds NBRVF.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NBRVF as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NBRVF yet.
